Cardiac adverse event profiles of EGFR tyrosine kinase inhibitors: a disproportionality analysis using eudravigilance

10 May 2026 (16:00 - 17:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Yara Shhab

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

5 More presentations in this session

Presentation thumbnail

Current clinical use of edoxaban 15 mg in hospitalized patients with heart failure: analysis from the JROAD-DPC database

Doctor Y. Fujimoto (Tokyo, JP)

Abstract Slides

Presentation thumbnail

Anticoagulants and pulmonary embolism: the surprising impact of apixaban on bilateral embolism

Doctor R. Brandao (Amadora, PT)

Abstract Slides

Presentation thumbnail

Pulmonary Embolism in anticoagulated patients: a retrospective single-centered cohort comparing data from the PIOPED II study

Doctor R. Brandao (Amadora, PT)

Abstract Slides

Presentation thumbnail

Nonuse of oral anticoagulation and outcomes across the ejection-fraction spectrum in acute heart failure with atrial fibrillation

Doctor J. Yamamoto (Tokyo, JP)

Abstract Slides

Presentation thumbnail

Long-term clinical outcomes of vasodilating beta-blockers in acute myocardial infarction patients with preserved left ventricular ejection fraction after a successful stent implantation

Mr D. Lee (Jeju, KR)

Abstract Slides

Access the full session

Session thumbnail

ePosters in pharmacology and pharmacotherapy (1)

The Event

Event poster

Heart Failure 2026

10 May 2026 16:00 CET

You may be interested in

Webinar

Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer

Congress Session

Recent perspectives in cardio-oncology

Congress Session

Cardio-oncology: when therapy leads to failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources